Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + sitravatinib versus docetaxel in previously treated advanced or metastatic non-small cell lung cancer
2022-001779-15Phase 3Terminated
- Sponsor
- BeiGene
- Start
- Oct 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in non-small cell lung cancer (NSCLC) comparing tislelizumab + sitravatinib with docetaxel monotherapy (2 arms). Primary endpoint: overall survival. Started Oct 2022; status: terminated.
02
Drugs
tislelizumabsitravatinibdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2022-001779-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001779-15.